This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study (751)

This study has been completed.
Information provided by (Responsible Party):
Hoya Surgical Optics, Inc. Identifier:
First received: February 21, 2012
Last updated: March 23, 2015
Last verified: August 2012
To evaluate visual acuity and quality of vision in participants undergoing cataract surgery with a Hoya model 751 intra-ocular lens and to compare the visual results to the common monofocal lens in use.

Condition Intervention
Aphakia Cataract Device: Study IOL Device: Hoya iSert 751 Device: Negatively aspheric IOL

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Visual Quality Following Aspheric and Monovision Lens Implantation - a Comparative Clinical Study

Resource links provided by NLM:

Further study details as provided by Hoya Surgical Optics, Inc.:

Primary Outcome Measures:
  • Uncorrected Visual Acuity (UCVA) (ETDRS)for distance, intermediate and near [ Time Frame: Up to 3 months ]

Enrollment: 42
Study Start Date: February 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Both Eyes
Model 751 IOL implanted in both eyes.
Device: Study IOL
Aspheric IOL for correction of aphakia
Other Name: Hoya iSert 751 IOL
Experimental: Single eye
Model 751 IOL in one eye
Device: Hoya iSert 751
Model 751 in one eye, standard IOL in other eye
Other Name: Hoya iSert Model 751
Active Comparator: Control
Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
Device: Negatively aspheric IOL
Negatively aspheric IOL in both eyes
Other Name: Hoya iSert model 251 or equivalent


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Senile cataract
  • Patient identified as a candidate for cataract surgery and IOL implantation
  • Willing to sign informed consent document approved by the Ethical Committee
  • Willing to complete all required tests and exams per this protocol

Exclusion Criteria:

  • Amblyopia
  • History or evidence of any ocular disease that may affect visual acuity
  • Previous ocular surgery, including refraction surgery
  • Ocular anomalies (e.g. microphthalmos, kerataconous)
  • Subjects with greater than 1.0 D of corneal astigmatism
  • Subjects who experience intraoperative complications that could affect postoperative IOL centration or tilt
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01544777

Australia, Western Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
Sponsors and Collaborators
Hoya Surgical Optics, Inc.
Principal Investigator: Graham Barrett, MD Sir Charles Gairdner Hospital, Nedlans WA
  More Information

Responsible Party: Hoya Surgical Optics, Inc. Identifier: NCT01544777     History of Changes
Other Study ID Numbers: DOF-1
Study First Received: February 21, 2012
Last Updated: March 23, 2015

Keywords provided by Hoya Surgical Optics, Inc.:

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases processed this record on September 21, 2017